Technologies

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

Cheese making is an ancient practice to preserve  perishable food such as milk for a long time. The first phase of cheese making involves the addition of rennet of animal origin, which contains the enzymes necessary for the hydrolysis and coagulation of milk caseins, and for cheese ripening (mainly lipase/esterase).

Our team can develop low-cost ultra-flexible sensors integrated on plastic substrate for volatile organic compounds (VOCs) and gas detection. These devices combine scalable fabrication technologies, implementing active materials such as nanostructured metal oxides or stack of nanostructures decorated with metal nanoparticles, thus enabling a high sensitivity (in the range of hundreds of ppb). These devices can be applied to numerous industrial and commercial sectors and they can be embedded in systems that are more sophisticated.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.